Koen de Boulle1. 1. Aalst Dermatology Group, Aalst, Belgium. koendeboulle@pandora.be
Abstract
BACKGROUND: The clinical characteristics of botulinum toxin type A (BoNTA) depend on the formulation used. OBJECTIVE: To evaluate whether switching BoNTA formulations affects patient satisfaction. METHODS: Forty patients enrolled and all were satisfied or extremely satisfied with Allergan BoNTA (BoNTA-Allergan) treatment in the glabellar+/-crow's feet+/-forehead area(s) in the preceding 6 months. Once improvement from this previous treatment had started to diminish, treatment was replicated using Ipsen BoNTA (BoNTA-Ipsen) at a 1:2.5 dose ratio. RESULTS: The incidence of patients rating treatment as effective or very effective in making them look younger, look rested, and look less stressed was significantly higher with BoNTA-Allergan than BoNTA-Ipsen--83% versus 36%, 90% versus 39%, and 83% versus 33%, respectively--even though evaluations were performed a mean of 20 weeks after BoNTA-Allergan treatment and only 16 weeks after BoNTA-Ipsen treatment. The incidence of patients who were satisfied or extremely satisfied was 100% (BoNTA-Allergan) versus 31% (BoNTA-Ipsen). BoNTA-Allergan was preferred by 69% of patients. CONCLUSIONS: Efficacy, satisfaction, and product preference ratings strongly favor the use of BoNTA-Allergan over BoNTA-Ipsen in the treatment of upper facial lines. Many patients who are satisfied with BoNTA-Allergan treatment become less satisfied if they are switched to BoNTA-Ipsen.
BACKGROUND: The clinical characteristics of botulinum toxin type A (BoNTA) depend on the formulation used. OBJECTIVE: To evaluate whether switching BoNTA formulations affects patient satisfaction. METHODS: Forty patients enrolled and all were satisfied or extremely satisfied with Allergan BoNTA (BoNTA-Allergan) treatment in the glabellar+/-crow's feet+/-forehead area(s) in the preceding 6 months. Once improvement from this previous treatment had started to diminish, treatment was replicated using Ipsen BoNTA (BoNTA-Ipsen) at a 1:2.5 dose ratio. RESULTS: The incidence of patients rating treatment as effective or very effective in making them look younger, look rested, and look less stressed was significantly higher with BoNTA-Allergan than BoNTA-Ipsen--83% versus 36%, 90% versus 39%, and 83% versus 33%, respectively--even though evaluations were performed a mean of 20 weeks after BoNTA-Allergan treatment and only 16 weeks after BoNTA-Ipsen treatment. The incidence of patients who were satisfied or extremely satisfied was 100% (BoNTA-Allergan) versus 31% (BoNTA-Ipsen). BoNTA-Allergan was preferred by 69% of patients. CONCLUSIONS: Efficacy, satisfaction, and product preference ratings strongly favor the use of BoNTA-Allergan over BoNTA-Ipsen in the treatment of upper facial lines. Many patients who are satisfied with BoNTA-Allergan treatment become less satisfied if they are switched to BoNTA-Ipsen.
Authors: Mark Nestor; Joel L Cohen; Marina Landau; Said Hilton; Andreas Nikolis; Syed Haq; Maurizio Viel; Bill Andriopoulos; Inna Prygova; Keith Foster; Alessio Redaelli; Philippe Picaut Journal: J Clin Aesthet Dermatol Date: 2020-12-01
Authors: O P Kreyden; B Rzany; P Becker-Wegerich; C Boudny-Frey; P Carrozza-Merlani; M Hess-Schmid; B Schlagenhauff Journal: Hautarzt Date: 2015-02 Impact factor: 0.751